You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
醫藥股普遍造好 流感疫苗國內上市三葉草(02197.HK)續彈15%
官網《人民日報》健康客戶端報道,本月以來,內地醫藥領域學術會議陸續恢復。中國國際旅行衛生保健協會醫療物資與醫療合作分會秘書長陳紅彥表示,正常學術會議的恢復,有助行業重新回歸正軌。 醫藥股今天普遍造好兼跑贏大市,四價季節性流感疫苗於內地上市的三葉草生物-B(02197.HK)反覆續彈15%報1.01元,股價重越10天線(0.96元)。聯邦制藥(03933.HK)屢探頂,今天反覆高見8.19元創近三年高,現報8.08元,反覆升7.7% 信達生物(01801.HK)及藍籌藥明生物(02269.HK)續升逾半成,報39.75元及44.1元。藍籌石藥(01093.HK)及翰森製藥(03692.HK)升逾2.5%-3%,報5.9元及10.14元。 百濟神州(06160.HK)、藥明康德(02359.HK)、康方生物-B(09926.HK)、康希諾(06185.HK)及金斯瑞生物(01548.HK)升逾2%-3.5%,後兩者跑贏,報24.55元及19.54元,齊升3.6%。艾美疫苗(06660.HK)反覆回升5.6%報37.55元。 內地最新經濟數據普遍勝預期兼人行今天起下調存準金率25點子。恆指在金融股主導曾高見18,372,現報18,240,續彈192點或1.1%,總成交額749億元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account